Lipid nanocarriers as skin drug delivery systems: Properties, mechanisms of skin interactions and medical applications

Sala, M.; Diab, Roudayna; Elaı̈ssari, Abdelhamid; Fessi, Hatem

doi:10.1016/j.ijpharm.2017.10.046

Cited by 311 publications

(193 citation statements)

References 110 publications

Supporting

Mentioning

169

Contrasting

Unclassified

Order By: Relevance

“…Transmission Electron Microscopy (TEM) analysis showed that nanoparticles have a spherical and regular form ( Figure 4). Nanoparticles loaded indomethacin and NSSEO: are able to penetrate ex vivo fresh human skin:-The skin plays principal functions such as barrier role, temperature control role and repair role that contribute to homeostasis process of human body (Sala et al, 2018). Skin has a potential application in drug delivery thanks to its large surface area.…”

Section: Immunohistochemistry (Ihc) Study:-mentioning

confidence: 99%

“…Prevention of first pass metabolism, minimization of pain and possible controlled release of drugs are from the advantages of the Topical or transdermal delivery over the conventional oral and intravenous dosage forms (Desai et al, 2010). Skin drug delivery (SDD) that is a smart method to the treatment of many diseases, cover in general dermal and transdermal drug delivery (Sala et al, 2018). Active molecules after topical application of nanoparticles can be absorbed via pathways such as transcellular, intercellular or transappendageal ( Figure 5).…”

Section: Immunohistochemistry (Ihc) Study:-mentioning

confidence: 99%

See 1 more Smart Citation

Topical Co-Delivery of Indomethacin and Nigella Sativa L. Essential Oil in Poly- -Caprolactone Nanoparticles: In Vivo Study of Anti-Inflammatory Activity.

Badri¹,

Mohamed²,

Affendi³

et al. 2018

IJAR

View full text Add to dashboard Cite

Indomethacin is a potent, nonselective Non-steroidal Antiinflammatory Drug (NSAID) but its low water-solubility precludes its use as topical dosage form. As with other NSAIDs, the systemic delivery is associated with high risk of serious gastrointestinal adverse events including bleeding, ulceration and perforation of stomach and intestines. Here we demonstrate a safer way of administration i.e via topical demonstrating synergistic effects when co-delivered with Nigella sativa L. seeds essential oil (NSSEO) in the form of coencapsulated particles (~200 nm) of poly--caprolactone. The particles showed penetrability across stratum corneum to dermis layer in ex-vivo human skin. Further study in the xyline-induced ear edema in mice was performed, and co-encapsulated particles demonstrated highest antiinflammatory effect compared to indomethacin particles and indomethacin gels. Despite slower onset compared to indomethacin gels, the inflamed ear continued to show reduction in thickness over 8 hours of observation demonstrating synergistic and pro-longed effect contributed by NSSEO. In immunohistochemistry study of CD45+, the mice ears treated with co-encapsulated particles showed considerable reduction in lesions, epidermal-dermal separation and inflammatory cells (lymphocytes and neutrophils) infiltration as compared to other formulation. Based on microscopic evaluation, the anti-inflammatory inhibition effect of co-encapsulated particles is the highest (90%) followed by indomethacin particles (79%) and indomethacin gel (49%). The findings suggest not only skin permeability of indomethacin significantly improved but also the therapeutic effects, all provided by the presence of NSSEO in the particles. This study paves the way to

show abstract

Section: Immunohistochemistry (Ihc) Study:-mentioning

confidence: 99%

Section: Immunohistochemistry (Ihc) Study:-mentioning

confidence: 99%

Topical Co-Delivery of Indomethacin and Nigella Sativa L. Essential Oil in Poly- -Caprolactone Nanoparticles: In Vivo Study of Anti-Inflammatory Activity.

Badri¹,

Mohamed²,

Affendi³

et al. 2018

IJAR

View full text Add to dashboard Cite

show abstract

“…Moreover, the structural similarity and interactions between the epidermal lipids and the lipid matrix of SLNs could enhance the skin permeation of the encapsulated drugs. The nanosize, narrow size distribution and the greater surface area of SLNs also facilitate the drug penetration into skin [21][22][23] . The controlled drug release can be achieved by using solid lipids because the mobility of drug is significantly lower in solid lipid matrix than in an oil droplet.…”

Section: Introductionmentioning

confidence: 99%

Development and Statistical Optimization of Solid Lipid Nanoparticle Formulations of Fluticasone Propionate

Amasya

Sengel-Türk

Badıllı

et al. 2020

tjps

View full text Add to dashboard Cite

INTRODUCTION: The aim of this study was to develop Fluticasone propionate (FP)-loaded solid lipid nanoparticle (SLN) formulations using the factorial design approach. METHODS: Tristearin percentages (X1) (1%, 2% and 4%) and homogenization cycles (X2) (2, 4, 8 cycles) were selected as independent variables in the factorial design. SLN formulations were optimized by multiple regression analysis (MLR) to evaluate the influence of the selected process and formulation independent variables on SLNs characteristics namely as encapsulation efficiency (Q1) and particle size (Q2). Polydispersity index and surface charge of the SLNs were also evaluated in this research. Besides, transmission electron microscopy, Differential scanning calorimetry and in vitro drug relase studies were carried out on the optimum SLN formulation. RESULTS: MLR analysis indicated that as homogenization cycle (X2) increased in the production process, the mean particle size was decreased. DISCUSSION AND CONCLUSION: This research displayed that FP-encapsulated SLNs with desired characteristics can be produced by varied the production and content variables of the formulations. Özet GİRİŞ ve AMAÇ: Bu çalışmanın amacı, faktöriyel tasarım yaklaşımını kullanarak Flutikazon propiyonat (FP) yüklü katı lipid nanopartikül formülasyonları geliştirmektir. YÖNTEM ve GEREÇLER: Bu amaçla faktöriyel tasarımda Tristearin yüzdeleri (X1) (% 1, % 2 ve % 4) ve homojenizasyon döngüleri (X2) (2, 4 ve 8 döngü) bağımsız değişkenler olarak seçilmiştir. Seçilen işlem ve formülasyona ait bağımsız değişkenlerin, katı lipid nanopartikül formülasyonların enkapsülasyon etkinliği (Q1) ve partikül boyututları (Q2) üzerindeki etkisini değerlendirmek için çoklu regresyon analizi (MLR) ile optimize edilmiştir. Çalışmada ayrıca nanopartiküllere ait polidispersite indeksi ve yüzey yükleri de değerlendirilmiştir. Bunun yanı sıra optimum katı lipid nanopartikül formülasyonu üzerinde geçirimli elektron mikroskopu, difransiyel taramalı kalorimetre analizi ve in vitro etkin madde salım çalışmaları da yapılmıştır. BULGULAR: MLR analizi, üretim sürecinde homojenizasyon döngüsü (X2) arttıkça, ortalama partikül boyutunun azaldığını göstermiştir. TARTIŞMA ve SONUÇ: Bu araştırma, istenen özelliklere sahip FP yüklenmiş katı lipid nanopartiküllerin, formülasyonların üretim ve içerik değişkenlerini değiştirerek üretilebileceğini göstermektedir. Anahtar Kelimeler: Deneysel tasarım, Flutikazon propionat, Nanopartiküller u n c o r r e c t e d p r o o f

show abstract

Section: Adjuvants For the Transdermal Delivery Of Protein Therapeuticsmentioning

confidence: 99%

Recent Advances in the Transdermal Delivery of Protein Therapeutics with a Combinatorial System of Chemical Adjuvants and Physical Penetration Enhancements

Park

Lee

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

Since the development of protein‐based therapeutics, research has been underway to deliver protein therapeutics into the systemic circulation and target sites have been actively conducted. Most protein‐based therapeutics require parenteral administration, due to their intrinsic vulnerability and susceptibility to enzyme‐mediated degradation. Among the routes of administration, the transdermal delivery system has been regarded as a promising technique to deliver protein therapeutics, offering the advantages of painless administration, ease of termination, and avoidance of first‐pass metabolism. However, unlike small molecular drugs, protein therapeutics have limited skin penetration, due to their macromolecular and hydrophilic properties. Both cheimcal adjuvants (CAs)‐treatment methods and physical penetration enhancer methods (PPEs) have been utilized to increase skin permeability for protein therapeutics. The CAs, which include chemical penetration enhancers and nanocarriers, permit the protein therapeutics to transport easily into the skin, by modifying the stratum corneum (SC) or fabricating their stable formulation. The PPEs, including iontophoresis, electroporation, and ultrasound, can improve the skin permeability of the therapeutic agent through disrupting the SC. In this review, the techniques of both chemical and physical enhancement methods are introduced and an overview of the latest approaches to the transdermal delivery of protein therapeutics is provided.

show abstract

Lipid nanocarriers as skin drug delivery systems: Properties, mechanisms of skin interactions and medical applications

Cited by 311 publications

References 110 publications

Topical Co-Delivery of Indomethacin and Nigella Sativa L. Essential Oil in Poly- -Caprolactone Nanoparticles: In Vivo Study of Anti-Inflammatory Activity.

Topical Co-Delivery of Indomethacin and Nigella Sativa L. Essential Oil in Poly- -Caprolactone Nanoparticles: In Vivo Study of Anti-Inflammatory Activity.

Development and Statistical Optimization of Solid Lipid Nanoparticle Formulations of Fluticasone Propionate

Recent Advances in the Transdermal Delivery of Protein Therapeutics with a Combinatorial System of Chemical Adjuvants and Physical Penetration Enhancements

Contact Info

Product

Resources

About